FDA Reviews 7 Peptides, Lifts 2023 Compounding Ban After Kennedy Jr. Push

3 articles · Updated · Oprah Mag · May 12

The FDA said it will convene a summer panel to assess safety and other data on seven peptides, while removing several peptide types from its category 2 bulk-substances list.
That change could let compounding pharmacies sell some peptides again after a 2023 ban, broadening access to products popular in wellness and longevity circles.
Doctors cited in the report said evidence for many touted benefits still rests largely on animal or cell studies, leaving major gaps on human efficacy, dosing and long-term risks.
Safety concerns remain acute because peptides can be contaminated if poorly manufactured, and misuse without medical oversight could trigger serious harms including autoimmune disease or cancer.
The shift reflects Robert F. Kennedy Jr.'s push to make peptides more available through regulated compounders, even as experts warn the market remains ahead of the science.

With peptides lacking human safety trials, why is the government considering making them more accessible?

Are popular 'healing' peptides a wellness breakthrough or a public health gamble with unknown consequences?